The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ALS and acquired Mexico City-based ARJ
  • ARJ is the largest, private pharmaceutical testing lab in Latin America
  • Mexico is a growing contributor to the $20 billion global pharmaceutical testing market and an important hub for Latin and North America
  • ALS states the acquisition of ARJ supports its strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America

Brisbane-based ALS has acquired Laboratorios de Control ARJ (ARJ).

ALS is a leading testing, inspection, certification and verification company trying to expand its global presence.

Based in Mexico City, ARJ is the largest, private pharmaceutical testing lab in Latin America with revenues of over $30 million.

ARJ was founded in 1967 and has steadily grown its business, employing over 500 people. It specialises in providing quality control for medicines, biological products, generics, biosimilars, cosmetics and medical devices. It also services many of the world’s largest pharmaceutical companies.

Mexico is a growing contributor to the $20 billion global pharmaceutical testing market and an important hub for Latin and North America.

“ARJ has a world class operation and client base which offers us a strong platform to continue to grow our presence in key markets including Argentina, Brazil, Colombia, and Mexico. We welcome the ARJ team to ALS and look forward to our collaboration with them throughout the region,” ALS Managing Director and CEO Raj Naran said.

ALS’ acquisition of ARJ is supported by the company’s existing Life Sciences Latin America operations and is expected to benefit from Group’s regional and global presence to further expand their offerings to clients.

“The acquisition of ARJ aligns with our stated acquisition strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America,” Raj said.

ALQ by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…